Loading...
NBTX logo

Nanobiotix S.A.NasdaqGS:NBTX Stock Report

Market Cap US$2.0b
Share Price
n/a
1Y758.0%
7D14.3%
1D7.0%
Portfolio Value
​
View

Nanobiotix S.A.

NasdaqGS:NBTX Stock Report

Market Cap: US$2.0b

Nanobiotix (NBTX) Stock Overview

Operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. More details

NBTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Rewards

Trading at 41.6% below our estimate of its fair value

Earnings are forecast to grow 55.61% per year

Risk Analysis

Negative shareholders equity

Volatile share price over the past 3 months compared to the US market


NBTX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW499,625 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
499,625 investors already sharing narratives
View all narratives

Nanobiotix S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Nanobiotix
Historical stock prices
Current Share Price€41.10
52 Week High€57.14
52 Week Low€4.79
Beta0.56
1 Month Change15.91%
3 Month Change36.36%
1 Year Change758.04%
3 Year Change537.21%
5 Year Change176.95%
Change since IPO142.05%

Recent News & Updates

Seeking Alpha • Jun 25

Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform

Summary Nanobiotix is rated a strong speculative Buy, driven by risk-adjusted upside from its JNJ-1900 radioenhancer platform in partnership with Janssen. NBTX’s lead indication, head and neck cancer, offers a modeled $624M valuation, but lung cancer programs—despite higher risk—represent two-thirds of the $4.5B risk-adjusted opportunity. JNJ-1900’s platform potential is vast, with even low-probability broad adoption scenarios materially boosting valuation; upcoming clinical milestones in 2026–2027 are pivotal. Current cash runway extends into 2029, reducing near-term financing risk, while the Johnson & Johnson partnership de-risks late-stage development and supports multi-indication expansion. Current development programs target only a fraction of the potential injectable radiotherapy market, leaving substantial long-term platform optionality. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jun 25

Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform

Summary Nanobiotix is rated a strong speculative Buy, driven by risk-adjusted upside from its JNJ-1900 radioenhancer platform in partnership with Janssen. NBTX’s lead indication, head and neck cancer, offers a modeled $624M valuation, but lung cancer programs—despite higher risk—represent two-thirds of the $4.5B risk-adjusted opportunity. JNJ-1900’s platform potential is vast, with even low-probability broad adoption scenarios materially boosting valuation; upcoming clinical milestones in 2026–2027 are pivotal. Current cash runway extends into 2029, reducing near-term financing risk, while the Johnson & Johnson partnership de-risks late-stage development and supports multi-indication expansion. Current development programs target only a fraction of the potential injectable radiotherapy market, leaving substantial long-term platform optionality. Read the full article on Seeking Alpha
Seeking Alpha • Oct 18

Nanobiotix enters final agreement to restructure existing loan with EU's investment bank

French biotech Nanobiotix (NASDAQ:NBTX) on Tuesday said it had reached a final agreement with the European Investment Bank (EIB) to re-align about €30.7M in outstanding debt obligations with its expected development and commercialization timelines. The company had previously announced the agreement-in-principle with the EIB in mid-Sept. As per the newly executed final agreement, NBTX can now defer repayment of the remaining €25.3M of the loan set to be paid in two tranches up to June 2029. The restructuring agreement also includes a new milestone payment of €20M due in June 2029. U.S.-listed shares of NBTX -2.4% to $4 after hours.
Seeking Alpha • Sep 28

Nanobiotix GAAP EPS of -€0.76, revenue of €1.33M beats by €0.11M

Nanobiotix press release (NASDAQ:NBTX): 1H GAAP EPS of -€0.76. Revenue of €1.33M (+0.8% Y/Y) beats by €0.11M. Cash and Cash Equivalents: Cash and cash equivalents as of June 30, 2022, were €63.0 million, compared to €83.9 million as of December 31, 2021.
Seeking Alpha • Sep 12

Nanobiotix agrees in principle to restructure debt obligations with EU's investment bank

French biotech Nanobiotix (NASDAQ:NBTX) on Monday said it had reached an agreement in principle to restructure €30.7M in outstanding debt obligations related to its 2018 loan agreement with the European Investment Bank. NBTX said the debt restructuring was done to realign debt obligations with the company's development and commercialization timelines. The company said that execution of the amendment to the debt obligations is expected in Q4 2022 after the legal documents are finalized. "Restructuring existing debt obligations to extend the maturity date of the loan will enable Nanobiotix to drive priority development programs in 2023 by extending operating runway an additional quarter," NBTX CFO Bart Van Rhijn said in a statement. NBTX said the restructuring of the debt obligations combined with capital available through its existing equity line allows the company to extend its operating runway into Q1 2024. U.S.-listed shares of NBTX +0.2% to $4.17 in mid-day trading.
Seeking Alpha • Aug 01

French biotech Nanobiotix rebounds to post best ever 47% intraday gain

ADRs of Paris-based clinical-stage biotech Nanobiotix S.A. (NASDAQ:NBTX) recovered from a sharp selloff on Monday to record the biggest ever intraday gain thanks to strong trading volumes. Nanobiotix (NBTX) plunged nearly 30% on above-average volume to reach an all-time low on Friday. However, the stock has added ~47% on Monday, with nearly 34.4K ADRs changing hands compared to the 65-day average of ~1.1K. This quarter, Nanobiotix (NBTX) is on track to launch its first U.S. clinical trial sites in an ongoing pivotal Phase 3 trial for lead candidate NBTXR3 in head and neck squamous cell carcinoma. Its partner for the program, LianBio (LIAN) also plans to activate the first trial site and dose the first patient in Asia in H2 2022 for the candidate against the same indication.

Shareholder Returns

NBTXUS BiotechsUS Market
7D14.3%2.3%0.8%
1Y758.0%42.3%20.2%

Return vs Industry: NBTX exceeded the US Biotechs industry which returned 41.1% over the past year.

Return vs Market: NBTX exceeded the US Market which returned 18.6% over the past year.

Price Volatility

Is NBTX's price volatile compared to industry and market?
NBTX volatility
NBTX Average Weekly Movement12.9%
Biotechs Industry Average Movement10.3%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: NBTX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: NBTX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2003100Laurent Levywww.nanobiotix.com

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand.

Nanobiotix S.A. Fundamentals Summary

How do Nanobiotix's earnings and revenue compare to its market cap?
NBTX fundamental statistics
Market capUS$2.04b
Earnings (TTM)-US$27.42m
Revenue (TTM)US$37.29m
54.7x
P/S Ratio
-74.5x
P/E Ratio

Is NBTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NBTX income statement (TTM)
Revenue€32.59m
Cost of Revenue€0
Gross Profit€32.59m
Other Expenses€56.55m
Earnings-€23.96m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.47
Gross Margin100.00%
Net Profit Margin-73.52%
Debt/Equity Ratio-109.2%

How did NBTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 12:48
End of Day Share Price 2026/07/06 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nanobiotix S.A. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Philippa GardnerEdison Investment Research
Jonathan MillerEvercore ISI
Emmanuel ParotGilbert Dupont